144 related articles for article (PubMed ID: 38523292)
1. SGLT2 inhibition and three urological cancers: Up-to-date results.
Lin L; Ning K; Xiang L; Peng L; Li X
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3797. PubMed ID: 38523292
[TBL] [Abstract][Full Text] [Related]
2. Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
Li B; Lin Y; Yang Y; Wang Z; Shi R; Zheng T; Liao B; Liao G; Huang J
Int Urol Nephrol; 2024 Apr; 56(4):1243-1251. PubMed ID: 38015384
[TBL] [Abstract][Full Text] [Related]
3. Association between cannabis use with urological cancers: A population-based cohort study and a mendelian randomization study in the UK biobank.
Huang J; Huang D; Ruan X; Huang J; Xu D; Heavey S; Olivier J; Na R
Cancer Med; 2023 Feb; 12(3):3468-3476. PubMed ID: 35975633
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibition, high-density lipoprotein, and kidney function: a mendelian randomization study.
Wang Z; Wei J; Zhao W; Shi R; Zhu Y; Li X; Wang D
Lipids Health Dis; 2024 Mar; 23(1):84. PubMed ID: 38509588
[TBL] [Abstract][Full Text] [Related]
5. Global Burden of Urologic Cancers, 1990-2013.
Dy GW; Gore JL; Forouzanfar MH; Naghavi M; Fitzmaurice C
Eur Urol; 2017 Mar; 71(3):437-446. PubMed ID: 28029399
[TBL] [Abstract][Full Text] [Related]
6. Gout patients have an increased risk of developing most cancers, especially urological cancers.
Chen CJ; Yen JH; Chang SJ
Scand J Rheumatol; 2014; 43(5):385-90. PubMed ID: 24825466
[TBL] [Abstract][Full Text] [Related]
7. Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study.
Jiang R; Wang X; Li Z; Cai H; Sun Z; Wu S; Chen S; Hu H
BMC Urol; 2023 Sep; 23(1):150. PubMed ID: 37736725
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.
Li J; Yu Y; Sun Y; Yu B; Tan X; Wang B; Lu Y; Wang N
Cardiovasc Diabetol; 2023 Oct; 22(1):278. PubMed ID: 37848934
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.
Xu M; Zheng J; Hou T; Lin H; Wang T; Wang S; Lu J; Zhao Z; Li M; Xu Y; Ning G; Bi Y; Wang W
Diabetes Care; 2022 Nov; 45(11):2718-2728. PubMed ID: 36161993
[TBL] [Abstract][Full Text] [Related]
10. Causal Estimation of Long-term Intervention Cost-effectiveness Using Genetic Instrumental Variables: An Application to Cancer.
Dixon P; Martin RM; Harrison S
Med Decis Making; 2024 Apr; 44(3):283-295. PubMed ID: 38426435
[TBL] [Abstract][Full Text] [Related]
11. A Large Genetic Causal Analysis of the Gut Microbiota and Urological Cancers: A Bidirectional Mendelian Randomization Study.
Yin Z; Liu B; Feng S; He Y; Tang C; Chen P; Wang X; Wang K
Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764869
[TBL] [Abstract][Full Text] [Related]
12. The current landscape of m6A modification in urological cancers.
Zeng Y; Lv C; Wan B; Gong B
PeerJ; 2023; 11():e16023. PubMed ID: 37701836
[TBL] [Abstract][Full Text] [Related]
13. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
Saito K; Kihara K
Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
[TBL] [Abstract][Full Text] [Related]
14. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response.
Xu B; Li S; Kang B; Fan S; Chen C; Li W; Chen J; He Z; Tang F; Zhou J
Mol Biol Rep; 2023 Nov; 50(11):9637-9647. PubMed ID: 37819499
[TBL] [Abstract][Full Text] [Related]
15. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
[TBL] [Abstract][Full Text] [Related]
16. Significant association of catechol-O-methyltransferase Val158Met polymorphism with bladder cancer instead of prostate and kidney cancer.
Chen Y; Yu X; Li T; Yan H; Mo Z
Int J Biol Markers; 2016 May; 31(2):e110-7. PubMed ID: 27055785
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune disease and subsequent urological cancer.
Liu X; Ji J; Forsti A; Sundquist K; Sundquist J; Hemminki K
J Urol; 2013 Jun; 189(6):2262-8. PubMed ID: 23228387
[TBL] [Abstract][Full Text] [Related]
18. Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.
Wu L; Chaffee KG; Parker AS; Sicotte H; Petersen GM
Tumour Biol; 2015 Sep; 36(10):7431-7. PubMed ID: 25900876
[TBL] [Abstract][Full Text] [Related]
19. Increasing occurrence of urological cancers in Slovakia.
Plesko I; Obsitnikova A; Cuninkova M; Tomasek L; Stefanakova D; Kubik A
Neoplasma; 2004; 51(4):248-54. PubMed ID: 15254654
[TBL] [Abstract][Full Text] [Related]
20. [Primary urological cancers in a context of limited resources: Epidemiology and treatment].
Ouedraogo S; Traore MT; Kambire JL; Ouedraogo S; Bere B; Kabore AF
Bull Cancer; 2019 Oct; 106(10):868-874. PubMed ID: 31350015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
